WUXI BIO (02269) rose more than 6% again, gaining 5.6% to HK$43.72 at the time of writing, with a turnover of HK$878 million. The company recently issued a positive profit alert, forecasting 2025 revenue to increase approximately 16.7% to RMB217.9 billion. Net profit attributable to shareholders is expected to grow 46.3% year-on-year to RMB49.08 billion, while adjusted profit is projected to rise 22.0% to RMB65.86 billion. Gross margin is anticipated to improve to 46.0%, up about 5 percentage points. A research report from CLSA noted that WUXI BIO's performance forecast for the second half of 2025 indicates revenue growth of 17% year-on-year, largely in line with expectations. Adjusted net profit surged 31% year-on-year to RMB37 billion, significantly surpassing market forecasts. Gross margin increased by 6.2 percentage points year-on-year to 48.8%, representing a key positive surprise in the profit alert and the main driver of the better-than-expected earnings. The report stated that within China's CRO and CDMO sector, WUXI BIO remains one of the top stock picks.